Page 5 - Kymab News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Kymab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Kymab Today - Breaking & Trending Today
Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) have received a consensus rating of “Hold” from the twelve research firms that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and five have issued a buy recommendation on the […] ....
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) Director Johan Wedell-Wedellsborg purchased 101,740 shares of the business’s stock in a transaction on Monday, May 15th. The stock was purchased at an average price of $9.65 per share, for a total transaction of $981,791.00. Following the acquisition, the director now owns 4,280,205 shares of the company’s stock, […] ....
Wedbush upgraded shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating) from a neutral rating to an outperform rating in a report published on Wednesday morning, MarketBeat reports. They currently have $13.00 price objective on the stock, up from their prior price objective of $5.00. Wedbush also issued estimates for Y-mAbs Therapeutics’ Q2 2023 earnings at […] ....
Wedbush upgraded shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating) from a neutral rating to an outperform rating in a report issued on Wednesday, Marketbeat Ratings reports. Wedbush currently has $13.00 price target on the stock, up from their prior price target of $5.00. Wedbush also issued estimates for Y-mAbs Therapeutics’ Q2 2023 earnings at […] ....
Wedbush upgraded shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating) from a neutral rating to an outperform rating in a report released on Wednesday, Marketbeat.com reports. Wedbush currently has $13.00 price target on the stock, up from their prior price target of $5.00. Wedbush also issued estimates for Y-mAbs Therapeutics’ Q2 2023 earnings at ($0.23) […] ....